Barclays
GBIO

Barclays’s Generation Bio GBIO Stock Holding History

Barclays’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,148
Closed -$3.67K – 5572
2025
Q2 		$3.67K Sell
1,148
-4,967
-81% -$19.1K ﹤0.01% 4998
2025
Q1 		$24.8K Sell
6,115
-2,475
-29% -$17.4K ﹤0.01% 4758
2024
Q4 		$91.1K Buy
8,590
+947
+12% +$16.9K ﹤0.01% 4613
2024
Q3 		$189K Buy
7,643
+4,764
+165% +$126K ﹤0.01% 4332
2024
Q2 		$81.2K Sell
2,879
-862
-23% -$28K ﹤0.01% 4010
2024
Q1 		$152K Sell
3,741
-3,045
-45% -$71.7K ﹤0.01% 4249
2023
Q4 		$112K Buy
6,786
+5,427
+399% +$94.6K ﹤0.01% 4615
2023
Q3 		$51.5K Sell
1,359
-381
-22% -$18K ﹤0.01% 3858
2023
Q2 		$95.7K Sell
1,740
-1,279
-42% -$58.7K ﹤0.01% 3579
2023
Q1 		$130K Buy
3,019
+1,728
+134% +$83.6K ﹤0.01% 4043
2022
Q4 		$50.7K Buy
1,291
+1,087
+533% +$57.1K ﹤0.01% 4544
2022
Q3 		$11K Sell
204
-49
-19% -$3.06K ﹤0.01% 4256
2022
Q2 		$17K Sell
253
-476
-65% -$31.1K ﹤0.01% 4456
2022
Q1 		$54K Buy
+729
New +$42.2K ﹤0.01% 4089

Other funds holding GBIO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barclays's GBIO Position: Q3 2025 in Review

Barclays sold out of Generation Bio (GBIO) in Q3 2025, closing a stake of 1,148 shares — an estimated $3.67K sold.

Barclays first reported a position in GBIO in Q1 2022 and held it in 14 quarters. The position peaked at $189K in Q3 2024. 41 funds tracked by Wall St. Rank hold GBIO as of Q3 2025.

  • Barclays reported no remaining Generation Bio position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 1,148 Generation Bio shares in Q3 2025, an estimated $3.67K.
  • Barclays first reported a position in Generation Bio in Q1 2022 and held it in 14 quarters.
  • Barclays's Generation Bio position peaked at $189K in Q3 2024.
  • 41 funds tracked by Wall St. Rank held Generation Bio as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.